I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically ...

Researchers Discover a Mechanism That Impairs Synaptic Plasticity in the Brains of Schizophrenia Patients Sep. 4, 2024 — A study mapped genes linked to schizophrenia and uncovered a mechanism ...

Symptoms of schizophrenia, a serious mental disorder that can include hallucinations and delusions, vary greatly from person to person. One common group of schizophrenia symptoms that doesn’t ...

There is evidence indicating the disorder shares an underlying genetic architecture with schizophrenia, and social withdrawal is a characteristic of both disorders. Most important, people with ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, ...

Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, which affects 24 million people globally. These voices often bully or abuse the ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...

Scott de Molitor, who suffers from schizophrenia, was found not criminally responsible after Justice Nancy Dilts ruled he was in a psychotic state at the time of the killing and could not ...

According to the company, preliminary results demonstrated a dose-dependent effect of ANAVEX 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX3-71 compared to ...

Teva Pharmaceuticals’ TEV-‘749 (olanzapine) has shown statistical improvement in schizophrenia symptoms in a Phase III trial. The Phase III SOLARIS trial (NCT05693935) demonstrated ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to ...